ARTICLE | Clinical News

AS1411: Phase I data

May 23, 2005 7:00 AM UTC

Data from a Phase I trial in 17 patients showed that AS1411 was safe and well tolerated. Also, 7 patients showed stable disease for 2 months or more and 1 patient had a near complete response. ASM pla...